Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Rhabdoid Tumor 7Medulloblastoma 7Glioma 7Wilms Tumor 6Sarcoma 6Osteosarcoma 6Neuroectodermal Tumors, Primitive, Peripheral 6Neuroblastoma 6Lymphoma, Non-Hodgkin 6Histiocytosis, Langerhans-Cell 6Hepatoblastoma 6Ependymoma 6Central Nervous System Neoplasms 6Rhabdomyosarcoma 5Sarcoma, Ewing 3Neoplasm Metastasis 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neuroendocrine Tumors 2Lung Neoplasms 2Burkitt Lymphoma 2Xanthogranuloma, Juvenile 1Triple Negative Breast Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Intraductal Neoplasms 1Ovarian Neoplasms 1Non functioning pancreatic endocrine tumor 1Nasopharyngeal Carcinoma 1Lymphoma 1Immunoglobulin Light-chain Amyloidosis 1Histiocytic Sarcoma 1

Interventions

Specimen Handling 2Magnetic Resonance Spectroscopy 2atezolizumab 1X-Rays 1Tiragolumab 1Phantoms, Imaging 1Nivolumab 1Ipilimumab 1Gelclair 1Fluorodeoxyglucose F18 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Chordoma × Phantoms, Imaging × Clear all
NCT05286801 2026-05-13

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
86 enrolled
Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡